HRAS and head and neck squamous cell carcinoma: Given that TP53 mutations (a) occur in ∼ 72 % of HNSCC cases with enrichment in the HPV neg group, (b) confer cisplatin resistance, (c) are currently undruggable [31,32], and (d) can co-occur with HRAS mutations, venetoclax represents a realistic treatment option for a subset of HNSCC patients.